Dermata Therapeutics Inc. has announced a change in its certifying accountants following the merger of Moss Adams LLP with Baker Tilly US, LLP, effective June 3, 2025. The audit committee of Dermata's Board of Directors has approved the appointment of Baker Tilly as the company's new independent registered public accounting firm, succeeding Moss Adams. The transition comes without any disagreements or reportable events regarding accounting principles or practices during the years 2023 and 2024, as well as the interim period through June 3, 2025. Moss Adams' audit reports for these years did not contain adverse opinions but included an explanatory paragraph about a going concern uncertainty.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。